Aspects of anti-Helicobacter pylori eradication therapy

  • G. N. J. Tytgat


The flood of data related to H. pylori eradication continues to appear, and further fuels the level of confusion about the choice of treatment, not only in the primary-care setting but also in referral centres. Many studies contribute to confusion because they lack power, because they fail to register primary or secondary resistance; because they fail to provide data ‘per protocol’ or ‘intention to treat’ or ‘all patients treated’ analysis; because they fail to monitor side-effect profiles but above all because they lack state-of-the-art monitoring of antimicrobial efficacy.


Proton Pump Inhibitor Antimicrob Agent Pylorus Eradication Antimicrobial Efficacy Pylorus Eradication Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tytgat GNJ. Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther. 1994;8:359–68.PubMedCrossRefGoogle Scholar
  2. 2.
    Axon ATR. Eradication of Helicobacter pylori. Scand J Gastroenterol. 1996;31(Suppl. 214):47–53.CrossRefGoogle Scholar
  3. 3.
    Tytgat GNJ. Current indications for Helicobacter pylori eradication therapy. Scand J Gastroenterol. 1996;31(Suppl.215):70–3.CrossRefGoogle Scholar
  4. 4.
    van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1966;1:6–19.CrossRefGoogle Scholar
  5. 5.
    Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol. 1996;91:246–52.PubMedGoogle Scholar
  6. 6.
    Al-Assi MT, Genta RM, Karttunen TJ, Cole RA, Graham DY. Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline and bismuth. Am J Gastroenterol. 1995; 90:403–4.PubMedGoogle Scholar
  7. 7.
    Iwahi T, Satoh H, Nakao M, Iwasaki T, Kubo K, Tamura T, Imada A. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother. 1991;35:490–6.PubMedGoogle Scholar
  8. 8.
    Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother. 1991;35:490–6.Google Scholar
  9. 9.
    McGowan CC, Cover TL, Blaser MJ. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology. 1994; 107:1573–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Darmaillac V, Bouchand S, Lamouliatte H, Mégraud F. Macrolides and Helicobacter pylori determination of MICs and effect of pH. Gut. 1995;37(Suppl. 1):361:A91.CrossRefGoogle Scholar
  11. 11.
    Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbial Infect Dis. 1989;8:888–9.CrossRefGoogle Scholar
  12. 12.
    Paulsen O, Höglund P, Walder M. No effect of omeprazole-induced hypoacidity on the bioavailability of amoxillin or bacampicillin. Scand J Infect Dis. 1989;21:219–23.PubMedCrossRefGoogle Scholar
  13. 13.
    Pommerien W, Braun M, Idström JP, Wrangsstadh M, Londong W. No interaction between omeprazole and amoxillin during combination therapy in Helicobacter prylori-positive subjects. Gastroenterology. 1995; 108:A194.CrossRefGoogle Scholar
  14. 14.
    Gustavson LE, Kaiser JF, Mukherjee DX, De Bartolo M, Schneck DW. Evaluation of pharmacokinetic drug interactions between clarithromycin and omeprazole. Am J Gastroenterol. 1994;89:1373 (abstract).Google Scholar
  15. 15.
    Goddard AF, Spiller RC. The effect of omeprazole on gastric juice viscosity, pH and bacterial counts. Aliment Pharmacol Ther. 1996;10:105–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Benini L, Castellani G, Bardelli E et al. Omeprazole causes delay in gastric emptying of digestible meals. Dig Dis Sci. 1996;41:469–74.PubMedCrossRefGoogle Scholar
  17. 17.
    de Boer WA, Tytgat GNJ. Ninety percent cure: which anti-Helicobacter pylori therapy can achieve this treatment goal? Am J Gastroenterol. 1995;90:1381–2 (editorial).PubMedGoogle Scholar
  18. 18.
    Ling TKW, Cheng AFB, Sung JJY, Yiu PYL, Chung SSC. An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study. Helicobacter. 1996;2:57–61.CrossRefGoogle Scholar
  19. 19.
    Xia HA, Keane CT, Beattie S, O’Morain CA. Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother. 1994;38:2357–61.PubMedGoogle Scholar
  20. 20.
    Hirschl AM, Hirschl MM, Rotter ML. Comparison of three methods of the sensitivity of Helicobacter pylori to metronidazole. J Antimicrob Chemother. 1993;32:45–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Witteman EM, Hopman WPM, Becx MCJ et al. Smoking habits and the acquisition of metronidazole resistance in patients with Helicobacter pylori-related gastritis. Aliment Pharmacol Ther. 1993;7:683–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother. 1992;29:115–20.PubMedCrossRefGoogle Scholar
  23. 23.
    VanZwet AA, Thijs JC, de Graaf B. Explanations for high rates of eradication with triple therapy using metronidazole-resistant Helicobacter pylori strains. Antimicrob Agents Chemother. 1992; 36:163–6.Google Scholar
  24. 24.
    Xia JA, Keane CT, Beattic S, O’Morain CA. Culture of Helicobacter pylori under aerobic conditions on solid media. Eur J Clin Microb Infect Dis. 1994;13:406–9.CrossRefGoogle Scholar
  25. 25.
    Smith MA, Edwards DI. Redox potential and oxygen concentration as factors in susceptibility of Helicobacter pylori to nitroheterocyclic drugs. J Antimicrob Chemother. 1995;35:751–64.PubMedCrossRefGoogle Scholar
  26. 26.
    Weel JFL, van der Hulst RWM, Gerrits Y, Tytgat GNJ, van der Ende A, Dankert J. Heterogeneity in susceptibility to metronidazole among Helicobacter pylori isolates from patients with gastritis or peptic ulcer disease. J Clin Microbiol. 1996;34:(in press).Google Scholar
  27. 27.
    Rautelin H, Seppälä K, Renkonen OV, Vainio U, Kosunen TU. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother. 1992;36:163–6.PubMedGoogle Scholar
  28. 28.
    Noach LA, Langenberg WL, Bertola MA, Dankert J, Tytgat GN. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis. 1994;26:321–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Al-Assi, Genta RM, Kartrunen TJ, Graham DY. Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1994;8:453–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Cayla R, Lamouliatte HC, Brugman M, Mégraud F. Pre-treatment resistances of Helicobacter pylori to metronidazole and macrolides. Acta Gastroenterol Belg. 56(Suppl.):65.Google Scholar
  31. 31.
    Cederberg C, Ekenved G, Lind T, Olbe L. Acid inhibitory characteristics of omeprazole in man. Scand J Gastroenterol. 1985;20(Suppl. 108):105–12.CrossRefGoogle Scholar
  32. 32.
    Cederberg C, Thomson ABR, Mahachai V et al. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology. 1992;103:913–18.PubMedGoogle Scholar
  33. 33.
    Damman HG, Richter G, Wolf N, Burkhardt F. Influence of lansoprazole 15 and 30 mg and omeprazole 20 and 40mg on meal-stimulated gastric acid secretion. Gut. 1995;37(Suppl. 2):A45–6.Google Scholar
  34. 34.
    Ripke H, Fuder H, Kleistl P et al. Intragastric pH under various dosage regimens of lansoprazole as compared to a reference treatment with omeprazole. Gut. 1995;37(Suppl. 2):A23.Google Scholar
  35. 35.
    Mégraud F, Boyanova L, Lamouliatte H. Activity of lansoprazole against Helicobacter pylori. Lancet. 1993;337:1486 (letter).CrossRefGoogle Scholar
  36. 36.
    Nagata K, Tagaki E, Tsuda M et al. Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease. Antimicrob Agents Chemother. 1995;39:567–70.PubMedGoogle Scholar
  37. 37.
    Takimoto T, Ido K, Taniguchi Y et al. Efficacy of lansoprazole in eradication of Helicobacter pylori. J Clin Gastroenterol. 1995;20(Suppl. 2):S121–4.PubMedCrossRefGoogle Scholar
  38. 38.
    de Boer WA, van Etten RJXM, Lai J, Schneeberger P, v.d. Wouw BAM, Driessen WMM. Effectiveness of 7-day quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection Helicobacter. 1996;l:(in press).Google Scholar
  39. 39.
    Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol. 1994;29(Suppl. 201):16–23.CrossRefGoogle Scholar
  40. 40.
    Harris A, Misiewicz JJ. Hitting H. pylori for four. Lancet. 1995;345:806–7 (editorial).PubMedCrossRefGoogle Scholar
  41. 41.
    de Boer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. J Clin Gastroenterol. 1996 (in press).Google Scholar
  42. 42.
    v.d. Hulst RWM, Weel JFL, Verheul SB et al. Treatment of H. pylori infection with low or high dose omeprazole combined with amoxicillin and the effect of early treatment: a prospective randomized double blind study. Aliment Pharmacol Ther. 1996;10:165–71.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers and Axcan Pharma 1996

Authors and Affiliations

  • G. N. J. Tytgat

There are no affiliations available

Personalised recommendations